Ad is loading...
GENE
Price
$0.77
Change
-$0.00 (-0.00%)
Updated
Oct 16, 04:59 PM (EDT)
LUCD
Price
$1.00
Change
-$0.00 (-0.00%)
Updated
Nov 22, 02:58 PM (EDT)
129 days until earnings call
Ad is loading...

GENE vs LUCD

Header iconGENE vs LUCD Comparison
Open Charts GENE vs LUCDBanner chart's image
Genetic Technologies
Price$0.77
Change-$0.00 (-0.00%)
Volume$201
CapitalizationN/A
Lucid Diagnostics
Price$1.00
Change-$0.00 (-0.00%)
Volume$100
CapitalizationN/A
GENE vs LUCD Comparison Chart
Loading...
LUCD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GENE vs. LUCD commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GENE is a Sell and LUCD is a Hold.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (GENE: $0.76 vs. LUCD: $1.00)
Brand notoriety: GENE and LUCD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GENE: 88% vs. LUCD: 93%
Market capitalization -- GENE: $10.53M vs. LUCD: $42.94M
GENE [@Medical Specialties] is valued at $10.53M. LUCD’s [@Medical Specialties] market capitalization is $42.94M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GENE’s FA Score shows that 0 FA rating(s) are green whileLUCD’s FA Score has 0 green FA rating(s).

  • GENE’s FA Score: 0 green, 5 red.
  • LUCD’s FA Score: 0 green, 5 red.
According to our system of comparison, LUCD is a better buy in the long-term than GENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LUCD’s TA Score shows that 5 TA indicator(s) are bullish.

  • LUCD’s TA Score: 5 bullish, 5 bearish.

Price Growth

GENE (@Medical Specialties) experienced а 0.00% price change this week, while LUCD (@Medical Specialties) price change was -1.09% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.22%. For the same industry, the average monthly price growth was +1.01%, and the average quarterly price growth was -2.21%.

Reported Earning Dates

GENE is expected to report earnings on Feb 28, 2024.

LUCD is expected to report earnings on Mar 31, 2025.

Industries' Descriptions

@Medical Specialties (+3.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LUCD($42.9M) has a higher market cap than GENE($10.5M). LUCD YTD gains are higher at: -29.149 vs. GENE (-68.125). GENE has higher annual earnings (EBITDA): -12.07M vs. LUCD (-49.75M). LUCD has more cash in the bank: 18.9M vs. GENE (3.73M). GENE has less debt than LUCD: GENE (382K) vs LUCD (15.3M). GENE has higher revenues than LUCD: GENE (8.49M) vs LUCD (2.43M).
GENELUCDGENE / LUCD
Capitalization10.5M42.9M24%
EBITDA-12.07M-49.75M24%
Gain YTD-68.125-29.149234%
P/E RatioN/AN/A-
Revenue8.49M2.43M350%
Total Cash3.73M18.9M20%
Total Debt382K15.3M2%
FUNDAMENTALS RATINGS
GENE: Fundamental Ratings
GENE
OUTLOOK RATING
1..100
47
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LUCD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
LUCD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMBC14.000.39
+2.87%
Embecta Corp
ZBRA392.317.78
+2.02%
Zebra Technologies Corp
PAM82.280.39
+0.48%
Pampa Energia SA
QRTEB3.02N/A
N/A
Qurate Retail
SNTI2.12N/A
N/A
Senti Biosciences Inc.

GENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GENE has been loosely correlated with HSCS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GENE jumps, then HSCS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENE
1D Price
Change %
GENE100%
N/A
HSCS - GENE
46%
Loosely correlated
-0.76%
RSLS - GENE
45%
Loosely correlated
+10.71%
AXNX - GENE
32%
Poorly correlated
N/A
INSP - GENE
31%
Poorly correlated
+0.77%
STAA - GENE
31%
Poorly correlated
+1.18%
More

LUCD and

Correlation & Price change

A.I.dvisor tells us that LUCD and INGN have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LUCD and INGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LUCD
1D Price
Change %
LUCD100%
-0.10%
INGN - LUCD
26%
Poorly correlated
-2.64%
PAVM - LUCD
25%
Poorly correlated
-1.94%
GENE - LUCD
25%
Poorly correlated
N/A
NNOX - LUCD
24%
Poorly correlated
+4.58%
CVRX - LUCD
24%
Poorly correlated
+9.25%
More